Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial-Reference-Cited by-同舟云学术

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Published:2013-09 Issue:10 Volume:14 Page:981-988
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Garassino Marina Chiara,Martelli Olga,Broggini Massimo,Farina Gabriella,Veronese Silvio,Rulli Eliana,Bianchi Filippo,Bettini Anna,Longo Flavia,Moscetti Luca,Tomirotti Maurizio,Marabese Mirko,Ganzinelli Monica,Lauricella Calogero,Labianca Roberto,Floriani Irene,Giaccone Giuseppe,Torri Valter,Scanni Alberto,Marsoni Silvia

Publisher

Elsevier BV

Subject

Oncology

Reference39 articles.

1. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan;J Clin Oncol,2006

2. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens;Fossella;J Clin Oncol,2000

3. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy;Shepherd;J Clin Oncol,2000

4. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

5. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

Cited by 435 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrative Chinese-Western medicine strategy to overcome docetaxel resistance in prostate cancer;Journal of Ethnopharmacology;2024-09

2. Discovery of a prominent dual-target DDR1/EGFR inhibitor aimed DDR1/EGFR-positive NSCLC;Bioorganic Chemistry;2024-08

3. A Microfluidic Chip-Based Automated System for Whole-Course Monitoring the Drug Responses of Organoids;Analytical Chemistry;2024-06-04

4. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis;Targeted Oncology;2024-06-01

5. Seeing the Trees From the Forest: Challenges in Subgroup Analysis-Based Guidelines in Oncology;Oncology Reviews;2024-05-24